Cargando…

Real-World Experience with Dolutegravir-Based Two-Drug Regimens

BACKGROUND: Dolutegravir-based 2-drug regimens (DTG 2DRs) are now accepted as alternatives to 3-drug regimens for HIV antiretroviral treatment (ART); however, literature on physician drivers for prescribing DTG 2DR is sparse. This study evaluated treatment patterns of DTG 2DR components in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ward, Douglas, Ramgopal, Moti, Riedel, David J., Garris, Cindy, Dhir, Shelly, Waller, John, Roberts, Jenna, Mycock, Katie, Oglesby, Alan, Collins, Bonnie, Dominguez, Megan, Pike, James, Mrus, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364229/ https://www.ncbi.nlm.nih.gov/pubmed/32724674 http://dx.doi.org/10.1155/2020/5923256

Ejemplares similares

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

1278. Real World Treatment Experience of Single Tablet Dolutegravir/Lamivudine in Those Naïve to Treatment with Baseline Viral Loads ≥ 100,000 copies/mL in the US
por: Benson, Paul, et al.
Publicado: (2022)

1279. Real World Treatment Experience of Treatment-Naïve People with HIV who Initiated Treatment with Single Tablet Dolutegravir/Lamivudine in a Test and Treat setting in the US.
por: Kuretski, Jennifer, et al.
Publicado: (2022)

Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
por: Priest, Julie, et al.
Publicado: (2023)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021)

550. Adherence and Persistency With Modern Single vs. Multi-Tablet Antiretroviral (ARV) Regimens in First Treatment of HIV in Clinical Practice
por: Mills, Anthony, et al.
Publicado: (2018)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens
por: Rodrigues, Janine, et al.
Publicado: (2023)

1564. Virological Suppression in People with HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar across Age Groups despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis)
por: Brogan, Andrew P, et al.
Publicado: (2023)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

1704. Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) among People Living with Human Immunodeficiency Virus (PLWH)
por: Rawlings, Keith M, et al.
Publicado: (2020)

2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies
por: Oglesby, Alan, et al.
Publicado: (2019)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
por: Bonfanti, Paolo, et al.
Publicado: (2020)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen
por: Badat, Ahmed, et al.
Publicado: (2022)

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
por: Luetkemeyer, Anne F., et al.
Publicado: (2016)

Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens
por: Okoli, Chinyere, et al.
Publicado: (2021)

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study
por: Waller, John, et al.
Publicado: (2019)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?
por: Capetti, Amedeo F, et al.
Publicado: (2019)

Treatment Satisfaction and Its Associated Factors of Dolutegravir Based Regimen in a Resource Limited Setting
por: Mehari, Eden Abetu, et al.
Publicado: (2021)

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
por: Patel, Rickesh, et al.
Publicado: (2021)

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV
por: Martínez-Sanz, Javier, et al.
Publicado: (2022)

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2018)

Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports
por: Suzuki, Takefumi, et al.
Publicado: (2017)

Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania
por: Mutagonda, Ritah F., et al.
Publicado: (2022)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States
por: Butler, Karin, et al.
Publicado: (2021)

1255. Single-tablet Regimens (STR) Offer Better Persistence and Adherence, with Lower Costs by Adherence Status, than Multiple-tablet Regimens (MTR) for People Living with HIV (PLWH) Enrolled in Medicaid
por: Brogan, Andrew P, et al.
Publicado: (2022)

The promise of paediatric dolutegravir
por: Golin, Rachel, et al.
Publicado: (2021)

Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings
por: Nance, Robin, et al.
Publicado: (2017)

Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India
por: Zheng, Amy, et al.
Publicado: (2018)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
por: Verna, John, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8dv4ulrer65ja07skkpaurbnhh